ATRC Quote, Financials, Valuation and Earnings

Alphatec Holdings, Inc. has a net margin of -0.2% compared to AtriCure, Inc.'s net margin of -14.54%. AtriCure, Inc.'s return on equity of -6.2% beat Alphatec Holdings, Inc.'s return on equity of -1495.13%.

AtriCure, Inc. has a consensus price target of $52.33, signalling upside risk potential of 25.29%. On the other hand Alphatec Holdings, Inc. has an analysts' consensus of $24.62 which suggests that it could grow by 12.04%. Given that AtriCure, Inc. has higher upside potential than Alphatec Holdings, Inc., analysts believe AtriCure, Inc. is more attractive than Alphatec Holdings, Inc..

AtriCure, Inc. has a beta of 1.401, which suggesting that the stock is 40.078% more volatile than S&P 500. In comparison Alphatec Holdings, Inc. has a beta of 1.013, suggesting its more volatile than the S&P 500 by 1.311%.

AtriCure, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Alphatec Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. AtriCure, Inc. pays -- of its earnings as a dividend. Alphatec Holdings, Inc. pays out -- of its earnings as a dividend.

AtriCure, Inc. quarterly revenues are $134.3M, which are smaller than Alphatec Holdings, Inc. quarterly revenues of $196.5M. AtriCure, Inc.'s net income of -$267K is higher than Alphatec Holdings, Inc.'s net income of -$28.6M. Notably, AtriCure, Inc.'s price-to-earnings ratio is -- while Alphatec Holdings, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AtriCure, Inc. is 3.83x versus 4.47x for Alphatec Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Boston Scientific Corp. has a net margin of -0.2% compared to AtriCure, Inc.'s net margin of 14.91%. AtriCure, Inc.'s return on equity of -6.2% beat Boston Scientific Corp.'s return on equity of 12.46%.

AtriCure, Inc. has a consensus price target of $52.33, signalling upside risk potential of 25.29%. On the other hand Boston Scientific Corp. has an analysts' consensus of $125.86 which suggests that it could grow by 27.58%. Given that Boston Scientific Corp. has higher upside potential than AtriCure, Inc., analysts believe Boston Scientific Corp. is more attractive than AtriCure, Inc..

AtriCure, Inc. has a beta of 1.401, which suggesting that the stock is 40.078% more volatile than S&P 500. In comparison Boston Scientific Corp. has a beta of 0.670, suggesting its less volatile than the S&P 500 by 33.029%.

AtriCure, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Boston Scientific Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. AtriCure, Inc. pays -- of its earnings as a dividend. Boston Scientific Corp. pays out -- of its earnings as a dividend.

AtriCure, Inc. quarterly revenues are $134.3M, which are smaller than Boston Scientific Corp. quarterly revenues of $5.1B. AtriCure, Inc.'s net income of -$267K is lower than Boston Scientific Corp.'s net income of $755M. Notably, AtriCure, Inc.'s price-to-earnings ratio is -- while Boston Scientific Corp.'s PE ratio is 52.77x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AtriCure, Inc. is 3.83x versus 7.61x for Boston Scientific Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Perspective Therapeutics, Inc. has a net margin of -0.2% compared to AtriCure, Inc.'s net margin of -12425.36%. AtriCure, Inc.'s return on equity of -6.2% beat Perspective Therapeutics, Inc.'s return on equity of -37.63%.

AtriCure, Inc. has a consensus price target of $52.33, signalling upside risk potential of 25.29%. On the other hand Perspective Therapeutics, Inc. has an analysts' consensus of $12.3077 which suggests that it could grow by 328.84%. Given that Perspective Therapeutics, Inc. has higher upside potential than AtriCure, Inc., analysts believe Perspective Therapeutics, Inc. is more attractive than AtriCure, Inc..

AtriCure, Inc. has a beta of 1.401, which suggesting that the stock is 40.078% more volatile than S&P 500. In comparison Perspective Therapeutics, Inc. has a beta of 1.182, suggesting its more volatile than the S&P 500 by 18.151%.

AtriCure, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. AtriCure, Inc. pays -- of its earnings as a dividend. Perspective Therapeutics, Inc. pays out -- of its earnings as a dividend.

AtriCure, Inc. quarterly revenues are $134.3M, which are larger than Perspective Therapeutics, Inc. quarterly revenues of $209K. AtriCure, Inc.'s net income of -$267K is higher than Perspective Therapeutics, Inc.'s net income of -$26M. Notably, AtriCure, Inc.'s price-to-earnings ratio is -- while Perspective Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AtriCure, Inc. is 3.83x versus 194.60x for Perspective Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

iRhythm Technologies, Inc. has a net margin of -0.2% compared to AtriCure, Inc.'s net margin of -2.7%. AtriCure, Inc.'s return on equity of -6.2% beat iRhythm Technologies, Inc.'s return on equity of -54.18%.

AtriCure, Inc. has a consensus price target of $52.33, signalling upside risk potential of 25.29%. On the other hand iRhythm Technologies, Inc. has an analysts' consensus of $218.60 which suggests that it could grow by 16.66%. Given that AtriCure, Inc. has higher upside potential than iRhythm Technologies, Inc., analysts believe AtriCure, Inc. is more attractive than iRhythm Technologies, Inc..

AtriCure, Inc. has a beta of 1.401, which suggesting that the stock is 40.078% more volatile than S&P 500. In comparison iRhythm Technologies, Inc. has a beta of 1.121, suggesting its more volatile than the S&P 500 by 12.075%.

AtriCure, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. iRhythm Technologies, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. AtriCure, Inc. pays -- of its earnings as a dividend. iRhythm Technologies, Inc. pays out -- of its earnings as a dividend.

AtriCure, Inc. quarterly revenues are $134.3M, which are smaller than iRhythm Technologies, Inc. quarterly revenues of $192.9M. AtriCure, Inc.'s net income of -$267K is higher than iRhythm Technologies, Inc.'s net income of -$5.2M. Notably, AtriCure, Inc.'s price-to-earnings ratio is -- while iRhythm Technologies, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AtriCure, Inc. is 3.83x versus 8.47x for iRhythm Technologies, Inc.. Usually stocks with elevated PS ratios are considered overvalued.